

Making Cancer History®

# **Surgery and Neoadjuvant Treatments for Cutaneous SCC**

**Neil D. Gross, MD  
Professor, Head and Neck Surgery**

# Cutaneous SCC

- Increasing incidence
- Surgery +/- radiation therapy
- Highly morbid



# Neoadjuvant Immunotherapy for CSCC


## Study Design

Single institution

Open-label, non-randomized

Window-of-opportunity

N=20



# Neoadjuvant Immunotherapy for CSCC

## Inclusion Criteria

1. Primary or recurrent, advanced-stage (III/IV) cSCC
2. Surgery and radiation planned with curative intent
3. Measurable disease (>1.5cm) per RECIST 1.1

# Neoadjuvant Immunotherapy for CSCC

## Outcome Measures

### Primary:


- ORR using RECIST v1.1

### Secondary:

- Safety and tolerability
- Pathologic response rate, time to recurrence and patterns of failure
- 2-year DSS, DFS, OS (compared to historical)
- Correlatives

# Neoadjuvant Immunotherapy for CSCC

## Patient #2



# Neoadjuvant Immunotherapy for CSCC

## Patient #2

### DIAGNOSIS

#### A. RIGHT SUPERFICIAL PAROTID:

Salivary gland with fibrosis, negative for residual tumor (s/p neoadjuvant therapy)  
Eleven lymph nodes, negative for tumor (0/11)

#### B. RIGHT NECK DISSECTION LEVEL IIB:

Four lymph nodes and salivary tissue, negative for tumor (0/4)

#### C. RIGHT NECK DISSECTION LEVEL IIA:

Four lymph nodes, negative for tumor (0/4)

#### D. RIGHT NECK DISSECTION LEVELS III AND IV:

Six lymph nodes, negative for tumor (0/6)

#### E. RIGHT TISSUE OVER UPPER DIVISION NERVE:

Salivary tissue, negative for tumor

# Neoadjuvant Immunotherapy for CSCC

## Patient #5



# Neoadjuvant Immunotherapy for CSCC

## Patient #5




PRE




POST

# Neoadjuvant Immunotherapy for CSCC

## Patient #5



PRE



POST

# Neoadjuvant Immunotherapy for CSCC

## Patient #5

**Procedure:** Composite right ear resection, right parotidectomy, right partial temporal bone resection, and right neck dissection

**Tumor Site:** Periauricular skin

**Tumor Laterality:** Right

**Tumor Focality:** Unifocal

**Tumor Size**

**Greatest dimension (in centimeters):** residual 0.6 cm (post-treatment)

**Tumor Depth of Invasion (DOI):** N/A

**Histologic Type:** squamous carcinoma

**Specimen Margins:** Uninvolved by invasive tumor

**Lymphovascular Invasion:** Not identified

**Perineural Invasion:** Not identified

**Regional Lymph Nodes:** Assessed

**Number of Lymph Nodes Involved:** 0

**Number of Lymph Nodes Examined:** 76

**Pathologic Stage Classification (pTNM, AJCC 8th Edition)**

**Primary Tumor (pT):** ypT1


**Regional Lymph Nodes (pN):** ypN0

**Distant Metastasis (pM):** NA

# Neoadjuvant Immunotherapy for CSCC


## Results

### RECIST 1.1




# Neoadjuvant Immunotherapy for CSCC

## Results



# Neoadjuvant Immunotherapy for CSCC


## Correlative Studies



# Neoadjuvant Immunotherapy for CSCC

## Next Steps

### Confirmatory multicenter trial



# Questions

ngross@mdanderson.org

 @DrNeilGross



~~Cancer~~®